Table 1. Recent clinical trials evaluating oncolytic virotherapy in cancer patients*.

Virus	Indication(s)	Phase	Status	Route	Co-therapy	Ref.
CG0070	Bladder carcinoma	II/III	Not yet recruiting	Intravesical	As single agent	NCT01438112
CGTG-102	Solid tumors	I	Recruiting	i.t. and i.v.	Combined with cyclophosphamide	NCT01598129
			Not yet recruiting	i.t.	As single agent	NCT01437280
Coxsackievirus A21	Melanoma	II	Recruiting	i.t.	As single agent	NCT01227551
						NCT01636882
DNX-2401	GBM	I/II	Recruiting	CED	As single agent	NCT01582516
	Glioma	I	Recruiting	i.t.	As single agent	NCT00805376
GL-ONC1	HNC	I	Recruiting	i.v.	Combined with cisplatin and RT	NCT01584284
	Lung cancer	I	Recruiting	Intrapleural	As single agent	NCT01766739
	Peritoneal carcinomatosis	I/II	Recruiting	i.p.	As single agent	NCT01443260
	Solid tumors	I	Recruiting	i.v.	As single agent	NCT00794131
HF10	HNC Solid tumors	I	Recruiting	i.t.	As single agent	NCT01017185
HSV1716	Mesothelioma	I/II	Recruiting	Intrapleural	As single agent	NCT01721018
	Non-CNS solid tumors	I	Recruiting	i.t.	As single agent	NCT00931931
JX594	HCC	II	Recruiting	i.v.	As single agent	NCT01636284
				n.a.	Combined with BSC	NCT01387555
			Active not recruiting	i.v. and i.t.	Followed by sorafenib	NCT01171651
	CRC	I	Active not recruiting	i.v.	As single agent	NCT01380600
			Recruiting	i.v.	As single agent	NCT01469611
		I/II	Recruiting	i.v. and i.t.	Combined with irinotecan	NCT01394939
	Solid tumors	I	Active not recruiting	i.t.	As single agent	NCT01169584
				i.v.	As single agent	NCT00625456
Measles virus	Mesothelioma	I	Recruiting	Intrapleural	As single agent	NCT01503177
NDV-HUJ	GBM NB Sarcoma	I/II	Not yet recruiting	i.v.	As single agent	NCT01174537
NTX-010	Lung cancer	II	Recruiting	i.v.	As single agent	NCT01017601
	Neuroendocrine tumors	I	Recruiting	i.v.	Combined with cyclophosphamide	NCT01048892
ParvOryx	GBM	I/II	Recruiting	i.t. or i.v.	As single agent	NCT01301430
PVSRIPO	GBM	I	Recruiting	i.t.	As single agent	NCT01491893
Reolysin®	Breast carcinoma	II	Recruiting	n.a.	Combined with PTX	NCT01656538
	CRC	I	Active not recruiting	i.v.	Combined with FOLFIRI regimen	NCT01274624
		II	Recruiting	n.a.	Combined with BVC and FOLFOX regimen	NCT01622543
	HNC	II	Active not recruiting	i.v.	Combined with CBP and PTX	NCT00753038
		III	Active not recruiting	i.v.	Combined with CBP and PTX	NCT01166542
	Lung cancer	II	Recruiting	i.v.	Combined wit CBP and PTX	NCT00861627
						NCT00998192
					Combined with DCX or pemetrexed	NCT01708993
	Melanoma	II	Active not recruiting	i.v.	As single agent	NCT00651157
			Recruiting	i.v.	Combined with CBP and PTX	NCT00984464
	Multiple myeloma	I	Recruiting	i.v.	As single agent	NCT01533194
	Pancreatic cancer	II	Recruiting	i.v.	Combined with CBP and PTX	NCT01280058
			Active not recruiting	i.v.	Combined with gemcitabine	NCT00998322
	Pediatric solid tumors	I	Recruiting	i.v.	Combined with cyclophosphamide	NCT01240538
	Prostate cancer	II	Recruiting	n.a.	Combined with DCX and prednisone	NCT01619813
	Reproductive tract tumors	I	Recruiting	i.v. + i.p.	As single agent	NCT00602277
		II	Recruiting	i.v.	Combined with PTX	NCT01199263
Talimogene laherparepvec	Melanoma	I/II	Recruiting	i.t.	Combined with ipilimumab	NCT01740297
		III	Active not recruiting	i.t.	As single agent	NCT00769704
			Enrolling by invitation	i.t.	As single agent	NCT01368276
Toca 511	Astrocytoma GBM Oligoastrocytoma Oligodendroglioma	I	Recruiting	Resection cavity	As single agent	NCT01470794
		I/II	Recruiting	i.t.	Combined with 5-FC	NCT01156584
VSV-IFN-β	HCC	I	Recruiting	i.t.	As single agent	NCT01628640

Abbreviations: 5-FC, 5-fluorocytosine; BSC, best supportive care; BVC, bevacizumab; CBP, carboplatin; CED, convection enhanced delivery; CNS, central nervous system tumor; CRC, colorectal cancer; DCX, docetaxel; FOLFIRI, folinic acid, 5-fluorouracil, irinotecan; FOLFOX, folinic acid, 5-flurouracil, oxaliplatin; GBM, glioblastoma multiforme; HCC, hepatocellular carcinoma; HNC, head and neck cancer; HSV, herpes simplex virus; IFN, interferon; n.a., not available; i.p., intra peritoneum; i.t., intra tumorem; i.v., intra venam; NB, neuroblastoma; NDV, Newcastle disease virus; PTX, paclitaxel; RT, radiotherapy; VSV, vesicular stomatitis virus. *Started after January 1, 2008, and not withdrawn, terminated or completed on the day of submission.